<table border="0" cellpadding="5" width="550" cellspacing="5" height="400" >
<tr valign="top" height="400" >
<td tEditID="c1r1" style=" background-color:#FFFFFF; color:#000000; bEditID:r3st1; bLabel:main; font-size:12pt; font-family:arial;" aEditID="c1r1" locked="0" >
<![CDATA[<div style="color: rgb(0, 0, 0); font-family: arial; font-size: 12pt;"><div style="font-size: 12pt;"><font face="arial" style="font-size: 12pt;"><b>Clinical Trial Site:&nbsp;</b>{!Trial_Scope_Report_BMS__c.Clinical_Trial_Site_BMS__c}</font></div><div style="font-size: 12pt;"><b style="font-size: 12pt;">Date:&nbsp;</b><font face="arial">{!Trial_Scope_Report_BMS__c.Date_BMS__c}</font></div><div style="font-size: 12pt;"><font face="arial"><b>Principle Investigator &amp; Location:&nbsp;</b>{!Trial_Scope_Report_BMS__c.Investigator_Location_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><b>MSM:&nbsp;</b>{!Trial_Scope_Report_BMS__c.OwnerFullName}</font></div><div style="font-size: 12pt;"><br></div><div style="font-size: 12pt;"><font face="arial"><b><u>Question 1</u></b></font></div><div style="font-size: 12pt;"><b style="font-size: 12pt;">Was RCO/CRO/Site manager contacted?:&nbsp;</b><font face="arial">{!Trial_Scope_Report_BMS__c.Q1_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial" style="font-size: 12pt;"><b>If no, provide details:&nbsp;</b></font><font face="arial">{!Trial_Scope_Report_BMS__c.Q1_Comments_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><font face="arial"><b><u>Question 2</u></b></font></div><div style="font-size: 12pt;"><font face="arial"><b>Details of topics highlighted:&nbsp;</b>{!Trial_Scope_Report_BMS__c.Q2_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><font face="arial"><b><u>Question 3</u></b></font></div><div style="font-size: 12pt;"><font face="arial"><b>Were additional trainings required?&nbsp;</b>{!Trial_Scope_Report_BMS__c.Q3_1_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><b>If yes, select the additional trainings:&nbsp;</b>{!Trial_Scope_Report_BMS__c.Q3_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><b>Additional Comments:&nbsp;</b>{!Trial_Scope_Report_BMS__c.Q3_Comments_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><b><u>Question 4</u></b></div><div style="font-size: 12pt;"><b style="font-size: 12pt;">Have competing trials been identified?</b><font face="arial">{!Trial_Scope_Report_BMS__c.Q4_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial" style="font-size: 12pt;"><b>If yes, provide details:&nbsp;</b></font><font face="arial">{!Trial_Scope_Report_BMS__c.Q4_Comments_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><font face="arial"><b><u>Question 5</u></b></font></div><div style="font-size: 12pt;"><font face="arial"><b>Patient recruitment status:&nbsp;</b>{!Trial_Scope_Report_BMS__c.Q5_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><b><u>Question 6</u></b></div><div style="font-size: 12pt;"><b style="font-size: 12pt;">Any recruitment barriers identified?&nbsp;</b><font face="arial">{!Trial_Scope_Report_BMS__c.Q6_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><b>If yes, provide details:</b>{!Trial_Scope_Report_BMS__c.Q6_Comments_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><font face="arial"><b><u>Question 7</u></b></font></div><div style="font-size: 12pt;"><font face="arial"><b>Other study topics discussed?&nbsp;</b>{!Trial_Scope_Report_BMS__c.Q7_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><b>Additional Comments:</b>&nbsp;<b>&nbsp;</b>{!Trial_Scope_Report_BMS__c.Q7_Comments_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><font face="arial"><u style="font-weight: bold;">Question 8</u></font></div><div style="font-size: 12pt;"><b style="font-size: 12pt;">Was the most recent newsletter reviewed?&nbsp;</b><font face="arial">{!Trial_Scope_Report_BMS__c.Q8_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><b>Additional Comments:&nbsp;</b>{!Trial_Scope_Report_BMS__c.Q8_Comments_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><font face="arial"><b><u>Question 9</u></b></font></div><div style="font-size: 12pt;"><font face="arial"><b>Describe follow-up actions needed:</b>{!Trial_Scope_Report_BMS__c.Q9_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><font face="arial"><b><u>Question 10</u></b></font></div><div style="font-size: 12pt;"><font face="arial"><b>Names of site staff/CRO/RCO:&nbsp;</b>{!Trial_Scope_Report_BMS__c.Q10_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><font face="arial"><br></font></div><div style="font-size: 12pt;"><b><u>Additional Comments</u></b></div><div><font face="arial">{!Trial_Scope_Report_BMS__c.Q11_EU_TSR_BMS_EMEA__c}</font></div><div style="font-size: 12pt;"><b><u><br></u></b></div></div>]]></td>
</tr>
</table>